IN2015DN02335A - - Google Patents
Info
- Publication number
- IN2015DN02335A IN2015DN02335A IN2335DEN2015A IN2015DN02335A IN 2015DN02335 A IN2015DN02335 A IN 2015DN02335A IN 2335DEN2015 A IN2335DEN2015 A IN 2335DEN2015A IN 2015DN02335 A IN2015DN02335 A IN 2015DN02335A
- Authority
- IN
- India
- Prior art keywords
- relates
- present
- mva
- virus
- mva virus
- Prior art date
Links
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 abstract 5
- 206010046865 Vaccinia virus infection Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 208000007089 vaccinia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24061—Methods of inactivation or attenuation
- C12N2710/24064—Methods of inactivation or attenuation by serial passage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/069256 WO2014048500A1 (en) | 2012-09-28 | 2012-09-28 | Novel mva virus and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN02335A true IN2015DN02335A (en:Method) | 2015-08-28 |
Family
ID=46982581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2335DEN2015 IN2015DN02335A (en:Method) | 2012-09-28 | 2012-09-28 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9732325B2 (en:Method) |
| EP (1) | EP2900810B1 (en:Method) |
| JP (1) | JP2015535687A (en:Method) |
| CN (1) | CN104812894B (en:Method) |
| AU (1) | AU2012391162A1 (en:Method) |
| BR (1) | BR112015006798A2 (en:Method) |
| CA (1) | CA2885240A1 (en:Method) |
| DK (1) | DK2900810T3 (en:Method) |
| IN (1) | IN2015DN02335A (en:Method) |
| MX (1) | MX2015003687A (en:Method) |
| RU (1) | RU2015115898A (en:Method) |
| WO (1) | WO2014048500A1 (en:Method) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11104884B2 (en) | 2017-02-23 | 2021-08-31 | Probiogen Ab | Vaccinia virus vectors related to MVA with extensive genomic symmetries |
| WO2019089755A1 (en) | 2017-10-31 | 2019-05-09 | Western Oncolytics Ltd. | Platform oncolytic vector for systemic delivery |
| CN108371715A (zh) * | 2018-01-03 | 2018-08-07 | 肖小林 | 一种病毒的靶向性防治药物 |
| JP2021535730A (ja) * | 2018-05-11 | 2021-12-23 | シティ・オブ・ホープCity of Hope | 複数の部位メガロウイルス（ｃｍｖ）抗原の発現のためのｍｖａベクター及びその使用 |
| CA3104392A1 (en) | 2018-07-04 | 2020-01-09 | Probiogen Ag | Method for purifying an enveloped virus |
| JP2023552289A (ja) | 2020-11-19 | 2023-12-15 | カリヴィル イムノセラピューティクス， インコーポレイテッド | 腫瘍微小環境リモデリングによる腫瘍溶解性免疫療法 |
| WO2023128672A1 (ko) * | 2021-12-29 | 2023-07-06 | 재단법인 아산사회복지재단 | 외피외 바이러스 생산이 증가한 신규한 백시니아 바이러스 변이주 |
| WO2023223183A1 (en) | 2022-05-16 | 2023-11-23 | Crispr Therapeutics Ag | Picornaviral vectors for gene editing |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7645456B2 (en) * | 2001-04-23 | 2010-01-12 | Sanofi Pasteur Biologics Co. | Vaccinia virus strains |
| EP1601333B1 (en) * | 2003-02-20 | 2013-01-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services | Novel insertion sites in pox vectors |
-
2012
- 2012-09-28 MX MX2015003687A patent/MX2015003687A/es unknown
- 2012-09-28 EP EP12769398.4A patent/EP2900810B1/en active Active
- 2012-09-28 IN IN2335DEN2015 patent/IN2015DN02335A/en unknown
- 2012-09-28 AU AU2012391162A patent/AU2012391162A1/en not_active Abandoned
- 2012-09-28 RU RU2015115898A patent/RU2015115898A/ru not_active Application Discontinuation
- 2012-09-28 CN CN201280077370.4A patent/CN104812894B/zh active Active
- 2012-09-28 BR BR112015006798A patent/BR112015006798A2/pt not_active IP Right Cessation
- 2012-09-28 JP JP2015533460A patent/JP2015535687A/ja active Pending
- 2012-09-28 WO PCT/EP2012/069256 patent/WO2014048500A1/en active Application Filing
- 2012-09-28 CA CA2885240A patent/CA2885240A1/en not_active Abandoned
- 2012-09-28 US US14/431,814 patent/US9732325B2/en active Active
- 2012-09-28 DK DK12769398.4T patent/DK2900810T3/en active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2900810A1 (en) | 2015-08-05 |
| CN104812894B (zh) | 2021-10-22 |
| CA2885240A1 (en) | 2014-04-03 |
| MX2015003687A (es) | 2015-06-15 |
| CN104812894A (zh) | 2015-07-29 |
| BR112015006798A2 (pt) | 2017-11-21 |
| US9732325B2 (en) | 2017-08-15 |
| US20150299666A1 (en) | 2015-10-22 |
| RU2015115898A (ru) | 2016-11-20 |
| WO2014048500A1 (en) | 2014-04-03 |
| AU2012391162A1 (en) | 2015-04-09 |
| JP2015535687A (ja) | 2015-12-17 |
| DK2900810T3 (en) | 2019-04-29 |
| EP2900810B1 (en) | 2019-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN02335A (en:Method) | ||
| PH12015501354A1 (en) | Antiviral compounds | |
| MX360823B (es) | Vacunas individualizadas para el cancer. | |
| PH12014501702A1 (en) | Imidazopyrrolidinone compounds | |
| MX2013008850A (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
| TN2012000414A1 (en) | Forms of rifaximin and uses thereof | |
| MX2013008390A (es) | Preparacion de estructuras de metal-triazolato. | |
| MX2015012414A (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
| PH12017501539A1 (en) | Disacetoxytubulysin h and analogs thereof | |
| PH12013502442A1 (en) | Inactivated dengue virus vaccine | |
| NZ608143A (en) | Recombinant modified vaccinia virus ankara (mva) influenza vaccine | |
| CA2915027A1 (en) | Compositions and methods for administration of vaccines against dengue virus | |
| BR112015008824A2 (pt) | linhagens melhoradas de microalgas e processo das mesmas | |
| MY186134A (en) | Curcumin-peptide conjugates and formulations thereof | |
| WO2012047267A3 (en) | Polyvalent immunogen | |
| PH12014501388A1 (en) | A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv | |
| GB201017519D0 (en) | Vaccines | |
| PH12015500061A1 (en) | Method for preparing substituted triazolopyridines | |
| BR112015025697A2 (pt) | cepa do vírus vaccinia mutante, uso da cepa do vírus vaccinia mutante, método para a produção de um produto de gene recombinante e produto de gene recombinante | |
| MX355719B (es) | Composicion farmaceutica en forma de una suspension oral que comprende una fraccion flavonoica y goma de xantano. | |
| WO2014159501A3 (en) | Processes for preparing tetrahydroisoquinolines | |
| PH12014501313B1 (en) | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives | |
| AU2016286071A8 (en) | Total synthesis of shishijimicin A and analogs thereof | |
| WO2013083753A3 (en) | Identification of a swine parecho-like virus and applications | |
| WO2012131412A3 (en) | Pharmaceutical composition containing no, process for the preparation and use thereof |